United Therapeutics Co. (NASDAQ:UTHR) CFO James Edgemond Sells 7,782 Shares

United Therapeutics Co. (NASDAQ:UTHR) CFO James Edgemond sold 7,782 shares of the firm’s stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $366.99, for a total value of $2,855,916.18. Following the completion of the sale, the chief financial officer now directly owns 6,426 shares in the company, valued at approximately $2,358,277.74. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

James Edgemond also recently made the following trade(s):

• On Monday, October 14th, James Edgemond sold 7,792 shares of United Therapeutics stock. The shares were sold at an average price of $355.88, for a total value of $2,773,016.96.
• On Monday, October 7th, James Edgemond sold 7,794 shares of United Therapeutics stock. The stock was sold at an average price of $355.54, for a total transaction of $2,771,078.76.
• On Monday, September 30th, James Edgemond sold 7,792 shares of United Therapeutics stock. The shares were sold at an average price of $358.62, for a total transaction of $2,794,367.04.
• On Monday, September 23rd, James Edgemond sold 7,796 shares of United Therapeutics stock. The stock was sold at an average price of $354.04, for a total transaction of $2,760,095.84.
• On Monday, September 9th, James Edgemond sold 7,802 shares of United Therapeutics stock. The stock was sold at an average price of $345.41, for a total value of $2,694,888.82.
• On Tuesday, September 3rd, James Edgemond sold 7,785 shares of United Therapeutics stock. The shares were sold at an average price of $362.37, for a total value of $2,821,050.45.

United Therapeutics Price Performance

United Therapeutics stock opened at $352.58 on Thursday. The company’s 50 day moving average is $352.33 and its two-hundred day moving average is $310.92. The firm has a market cap of $15.69 billion, a PE ratio of 16.20, a price-to-earnings-growth ratio of 1.34 and a beta of 0.57. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $377.03.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The company had revenue of $714.90 million during the quarter, compared to analysts’ expectations of $691.87 million. During the same quarter last year, the business posted $5.24 earnings per share. The company’s revenue for the quarter was up 19.8% on a year-over-year basis. On average, research analysts expect that United Therapeutics Co. will post 24.72 EPS for the current fiscal year.

Analyst Ratings Changes

UTHR has been the subject of several research reports. Bank of America dropped their price target on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research report on Thursday, August 1st. HC Wainwright reaffirmed a “buy” rating and set a $400.00 target price on shares of United Therapeutics in a report on Thursday, August 1st. UBS Group raised their price target on shares of United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research note on Monday, July 8th. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Finally, Oppenheimer lifted their target price on United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a research report on Wednesday, August 28th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $361.33.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in UTHR. Mediolanum International Funds Ltd increased its stake in shares of United Therapeutics by 6.9% during the third quarter. Mediolanum International Funds Ltd now owns 4,804 shares of the biotechnology company’s stock worth $1,720,000 after buying an additional 312 shares during the period. Values First Advisors Inc. acquired a new position in United Therapeutics during the 3rd quarter worth approximately $90,000. Impact Partnership Wealth LLC purchased a new stake in shares of United Therapeutics in the 3rd quarter valued at approximately $254,000. Hennion & Walsh Asset Management Inc. raised its holdings in shares of United Therapeutics by 31.4% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 4,286 shares of the biotechnology company’s stock valued at $1,536,000 after purchasing an additional 1,023 shares in the last quarter. Finally, First National Bank of Hutchinson lifted its position in shares of United Therapeutics by 46.3% during the 3rd quarter. First National Bank of Hutchinson now owns 2,481 shares of the biotechnology company’s stock worth $889,000 after purchasing an additional 785 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.